ATEZOLIZUMAB AND HYALURONIDASE-TQJS

24 reported adverse events

Drug classes: Endoglycosidase [EPC] Programmed Death Receptor-1 Blocking Antibody [EPC]

These side effects are most commonly reported by patients taking ATEZOLIZUMAB AND HYALURONIDASE-TQJS:

# Side effect Count
0 INJECTION SITE PAIN 4
1 NO ADVERSE EVENT 4
2 BLISTER 2
3 MALAISE 2
4 PAIN 2
5 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 2
6 PRODUCT STORAGE ERROR 2
7 ABDOMINAL DISCOMFORT 1
8 BURNING SENSATION 1
9 DEATH 1
See all common reactions for ATEZOLIZUMAB AND HYALURONIDASE-TQJS

ATEZOLIZUMAB AND HYALURONIDASE-TQJS is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HILAR LYMPHADENOPATHY 1 0.0011
1 PRODUCT AFTER TASTE 1 0.0010
2 LYMPHADENOPATHY MEDIASTINAL 1 0.0005
3 INTERCEPTED PRODUCT STORAGE ERROR 1 0.0003
4 HEPATOCELLULAR CARCINOMA 1 0.0001
5 PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 2 0.0001
6 HEPATITIS 1 0.0000
7 PNEUMONITIS 1 0.0000
8 RESPIRATORY DISTRESS 1 0.0000
9 BLISTER 2 0.0000
See all enriched reactions for ATEZOLIZUMAB AND HYALURONIDASE-TQJS